PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22094768-9 2011 The in vivo study revealed that, compared with untreated control, rats administered adipose-derived stem cells along with transient antilymphocyte serum and cyclosporin A treatment had significantly prolonged allotransplant survival (p < 0.001), decreased allotissue rejection, significantly elevated donor cell chimerism, and increased CD4/CD25/Foxp3 regulatory T cells in peripheral blood and alloskin tissue with up-regulation of transforming growth factor-beta and interleukin-10 levels. Cyclosporine 157-170 interleukin 2 receptor subunit alpha Homo sapiens 344-348 22417245-0 2013 Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases. Cyclosporine 66-78 interleukin 2 receptor subunit alpha Homo sapiens 35-39 22944461-13 2012 Soluble IL-2R suppression implies a mechanism explaining the effects of CsA. Cyclosporine 72-75 interleukin 2 receptor subunit alpha Homo sapiens 8-13 25379560-10 2014 Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine. Cyclosporine 140-152 interleukin 2 receptor subunit alpha Homo sapiens 57-61 25379560-11 2014 At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P < 0.001). Cyclosporine 90-102 interleukin 2 receptor subunit alpha Homo sapiens 34-38 20595929-1 2010 BACKGROUND: IL2 receptor antagonist (IL2ra) induction therapy has gained favor due to an excellent safety profile and improved outcomes in randomized trials using cyclosporine-based immunosuppression. Cyclosporine 163-175 interleukin 2 receptor subunit alpha Homo sapiens 12-35 20595929-1 2010 BACKGROUND: IL2 receptor antagonist (IL2ra) induction therapy has gained favor due to an excellent safety profile and improved outcomes in randomized trials using cyclosporine-based immunosuppression. Cyclosporine 163-175 interleukin 2 receptor subunit alpha Homo sapiens 37-42 18957170-7 2008 PSP exhibited similar and additive inhibitory effects to ciclosporin to suppress activated T cell proliferation, Th1 cytokines and reduce CD3+/CD25+ cell expression, but not Th2 cytokine expression, which helps the cytokine balance shift towards Th2 dominance. Cyclosporine 57-68 interleukin 2 receptor subunit alpha Homo sapiens 143-147 20470309-8 2010 In intermediate-risk recipients, IL-2Ra induction was associated with a 26% reduction in the incidence of acute rejection; but this benefit was restricted only to recipients initiated on cyclosporine-based immunosuppressive regimens. Cyclosporine 187-199 interleukin 2 receptor subunit alpha Homo sapiens 33-39 20470309-11 2010 CONCLUSION: This registry analysis suggests that IL-2Ra induction may be associated with a reduction in rejection risk in cyclosporine-treated intermediate immunological risk recipients, but not in low-risk renal transplant recipients. Cyclosporine 122-134 interleukin 2 receptor subunit alpha Homo sapiens 49-55 19903662-3 2010 The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro. Cyclosporine 53-67 interleukin 2 receptor subunit alpha Homo sapiens 140-144 19903662-4 2010 METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA). Cyclosporine 129-143 interleukin 2 receptor subunit alpha Homo sapiens 15-19 19903662-8 2010 RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine. Cyclosporine 37-51 interleukin 2 receptor subunit alpha Homo sapiens 86-90 19903662-8 2010 RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine. Cyclosporine 37-49 interleukin 2 receptor subunit alpha Homo sapiens 86-90 17889153-11 2007 The logistic regression analysis (dependent variable: PTDM; independent variables: age, anti-CD25, tacrolimus vs cyclosporine) showed that treatment with anti-CD25 is an independent risk factor for PTDM (P = .041; OR 3.28; CI 95% 1.04-10.31). Cyclosporine 113-125 interleukin 2 receptor subunit alpha Homo sapiens 159-163 18424069-7 2008 The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA. Cyclosporine 37-40 interleukin 2 receptor subunit alpha Homo sapiens 102-106 18424069-7 2008 The mechanism might be the effect of CsA on the T cells activation because the expression of CD69 and CD25 molecules on T cells was markedly reduced in the presence of CsA. Cyclosporine 168-171 interleukin 2 receptor subunit alpha Homo sapiens 102-106 18477227-5 2008 The serum IL-2 receptor, TNF-alpha and IL-5 levels of patients before CsA treatment were statistically higher than those of the control group (P = 0.001), and after 4 weeks of CsA therapy the mean IL-2R, TNF-alpha and IL-5 levels were significantly decreased. Cyclosporine 176-179 interleukin 2 receptor subunit alpha Homo sapiens 197-202 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Cyclosporine 94-106 interleukin 2 receptor subunit alpha Homo sapiens 161-165 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Cyclosporine 94-106 interleukin 2 receptor subunit alpha Homo sapiens 176-180 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Cyclosporine 94-106 interleukin 2 receptor subunit alpha Homo sapiens 176-180 18021968-2 2007 In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. Cyclosporine 108-111 interleukin 2 receptor subunit alpha Homo sapiens 161-165 18021968-9 2007 CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors. Cyclosporine 0-3 interleukin 2 receptor subunit alpha Homo sapiens 63-67 18021968-9 2007 CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors. Cyclosporine 0-3 interleukin 2 receptor subunit alpha Homo sapiens 90-94 17493526-13 2007 The percentage of CD4+CD25+ T cells was higher in the CsA group. Cyclosporine 54-57 interleukin 2 receptor subunit alpha Homo sapiens 22-26 16313313-5 2005 In this setting, use of an IL-2R antagonist with mycophenolate mofetil and steroids with delayed cyclosporine appears to be associated with a low incidence of biopsy-proven rejection and comparable renal function to patients with immediate function. Cyclosporine 97-109 interleukin 2 receptor subunit alpha Homo sapiens 27-32 17227295-5 2007 RESULTS: In group I, at time points C0 and C2, increased CsA-PK significantly inhibited expression of IL-2, IFN-gamma, PCNA and CD25 (P < 0.05). Cyclosporine 57-60 interleukin 2 receptor subunit alpha Homo sapiens 128-132 16126800-0 2006 An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. Cyclosporine 101-112 interleukin 2 receptor subunit alpha Homo sapiens 82-86 15282533-8 2004 Cyclosporine blocked the induction of CD25 expression on alloactivated T cells in vitro but had no detectable effect on CD25 expression by T-regulatory cells. Cyclosporine 0-12 interleukin 2 receptor subunit alpha Homo sapiens 38-42 16182762-1 2005 BACKGROUND: Basiliximab, a chimeric monoclonal antibody (mAb) directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), has been extensively evaluated as induction therapy for kidney transplant recipients, more frequently in combination with a cyclosporine-based regimen. Cyclosporine 264-276 interleukin 2 receptor subunit alpha Homo sapiens 133-137 15866683-8 2005 CONCLUSIONS: Between 1987 and 2002, CsA-based immunosuppression combined with MMF and Ste became the most commonly used strategy for both initial and maintenance therapy after kidney transplantation in Germany, yielding the low acute rejection rates particularly when combined with IL-2Ra. Cyclosporine 36-39 interleukin 2 receptor subunit alpha Homo sapiens 282-288 11773888-1 2001 BACKGROUND: Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. Cyclosporine 242-254 interleukin 2 receptor subunit alpha Homo sapiens 148-152 12197897-7 2002 These results indicate that activated Th1-type pulmonary T cells play an important role in the development of corticosteroid- resistant IP in DM/PM and that the increase in CD25+ CD8+ T cells in BALF is a useful indicator for corticosteroid-resistant IP in DM/PM and hence may be an indicator for early use of cyclosporin. Cyclosporine 310-321 interleukin 2 receptor subunit alpha Homo sapiens 173-177 12021552-7 2002 It was then shown that PP2 and cyclosporin A strongly inhibited CD25 expression in both clones, while wortmannin and Ro-31-8220 had more limited effects. Cyclosporine 31-44 interleukin 2 receptor subunit alpha Homo sapiens 64-68 15041317-5 2004 Induction therapy with OKT3, polyclonal antibodies, and more recently with anti IL-2R monoclonal antibodies allowed the delay of introduction cyclosporine in patients showing posttransplant graft dysfunction. Cyclosporine 142-154 interleukin 2 receptor subunit alpha Homo sapiens 80-85 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Cyclosporine 107-119 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Cyclosporine 156-168 interleukin 2 receptor subunit alpha Homo sapiens 4-9 12773967-6 2003 The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone. Cyclosporine 156-168 interleukin 2 receptor subunit alpha Homo sapiens 4-9 11773888-1 2001 BACKGROUND: Basiliximab (Simulect), a high-affinity chimeric, monoclonal antibody directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of acute renal allograft rejection when used in combination with cyclosporine (Neoral) and steroids. Cyclosporine 256-262 interleukin 2 receptor subunit alpha Homo sapiens 148-152 11571448-3 2001 We hypothesized that the addition of mycophenolate mofetil (MMF) and a humanized monoclonal anti-CD25 antibody (daclizumab) to a cyclosporine (CsA microemulsion)-based immunosuppression protocol would permit transplantation without steroids. Cyclosporine 129-141 interleukin 2 receptor subunit alpha Homo sapiens 97-101 11145094-1 2000 Four major double-blind randomized trials in kidney transplant patients have shown that the interleukin-2 receptor (IL-2R alpha) antagonists declizumab or basiliximab, when added to an immunosuppressive regimen consisting of cyclosporin and prednisone, reduce the incidence of acute rejections after kidney transplantation by 30-40%, during the first 6 months. Cyclosporine 225-236 interleukin 2 receptor subunit alpha Homo sapiens 116-127 11438213-5 2001 RESULTS: Although we observed differential CsA sensitivity of T-cell activation marker (CD69, CD45RO, CD25) upregulation comparing UCB and adult, we did not observe any significant difference in CsA sensitivity of T-cell effector functions. Cyclosporine 43-46 interleukin 2 receptor subunit alpha Homo sapiens 102-106 11604047-10 2001 Since these anti-IL-2R antibodies are well tolerated and since calcineurin inhibitors are intrinsically nephrotoxic, anti-IL-2R antibodies have been used in an attempt to avoid cyclosporin after transplantation. Cyclosporine 177-188 interleukin 2 receptor subunit alpha Homo sapiens 122-127 10762208-1 2000 BACKGROUND: Our purpose was to develop and evaluate protocols for selective immunosuppression after liver transplantation using the monoclonal antibodies (mAbs) NDS-61, directed against the interleukin-2 receptor (CD25), and 1A29, directed against the intercellular adhesion molecule-1 (CD54), in combination with subtherapeutic cyclosporine (CsA). Cyclosporine 329-341 interleukin 2 receptor subunit alpha Homo sapiens 214-218 11073027-2 2000 As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations. Cyclosporine 44-55 interleukin 2 receptor subunit alpha Homo sapiens 7-11 10844492-2 2000 We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody. Cyclosporine 80-91 interleukin 2 receptor subunit alpha Homo sapiens 158-180 10844492-2 2000 We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody. Cyclosporine 80-91 interleukin 2 receptor subunit alpha Homo sapiens 189-193 10762208-1 2000 BACKGROUND: Our purpose was to develop and evaluate protocols for selective immunosuppression after liver transplantation using the monoclonal antibodies (mAbs) NDS-61, directed against the interleukin-2 receptor (CD25), and 1A29, directed against the intercellular adhesion molecule-1 (CD54), in combination with subtherapeutic cyclosporine (CsA). Cyclosporine 343-346 interleukin 2 receptor subunit alpha Homo sapiens 214-218 10507492-9 1999 CONCLUSION: During the early posttransplant period anti-CD25 monoclonal antibodies combined with rapamycin and steroids offer a promising baseline therapy to avoid cyclosporine exposure and facilitate recovery from ischemic/reperfusion injuries. Cyclosporine 164-176 interleukin 2 receptor subunit alpha Homo sapiens 56-60 10729995-1 2000 This report details the effects of cyclosporin A (Cs-A) on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL) with an increase in circulating T cells that express CD3, CD8, CD25, CD45RO, and T-cell receptor alpha beta chain. Cyclosporine 35-48 interleukin 2 receptor subunit alpha Homo sapiens 189-193 10507492-0 1999 Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Cyclosporine 80-92 interleukin 2 receptor subunit alpha Homo sapiens 12-16 9950598-6 1999 There was a reduction from before CsA treatment to after CsA-treatment in the numbers of HLA-DR+ and IL-2R+ cells (P = 0.03), but the reduction in the epithelial cell HLA-DR expression did not reach significance. Cyclosporine 57-60 interleukin 2 receptor subunit alpha Homo sapiens 101-106 8557519-2 1995 We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2. Cyclosporine 20-23 interleukin 2 receptor subunit alpha Homo sapiens 44-49 9245491-0 1997 Suppression of dialysis patients" lymphocyte IL-2R expression by glucocorticoids and cyclosporine. Cyclosporine 85-97 interleukin 2 receptor subunit alpha Homo sapiens 45-50 7570986-5 1995 This nonresponsiveness induced by anti-LFA-3 or anti-IL-2/IL-2R could be overcome by the incorporation of cyclosporine during the first-round stimulation or by incorporation of IL-2 during the second-round stimulation. Cyclosporine 106-118 interleukin 2 receptor subunit alpha Homo sapiens 58-63 10559581-6 1999 Following CsA treatment, a significant decrease in the percentage of activated T cells expressing CD3+CD25+ and CD3+HLA-DR+ was noted at 6 and 12 months. Cyclosporine 10-13 interleukin 2 receptor subunit alpha Homo sapiens 102-106 8557519-1 1995 We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin. Cyclosporine 208-219 interleukin 2 receptor subunit alpha Homo sapiens 56-78 8557519-2 1995 We demonstrate that CsA and FK506 inhibited IL-2R (CD25) gene transcription and protein expression after stimulation by anti-CD3 or ionomycin, but not by phorbol ester or IL-2. Cyclosporine 20-23 interleukin 2 receptor subunit alpha Homo sapiens 51-55 8557519-1 1995 We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin. Cyclosporine 208-219 interleukin 2 receptor subunit alpha Homo sapiens 80-85 8557519-1 1995 We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin. Cyclosporine 221-224 interleukin 2 receptor subunit alpha Homo sapiens 56-78 8207202-6 1994 Cyclosporin A, which prevented lymphokine mRNA transcription, inhibited more than 90% of the IL-2R alpha and NF-kappa B levels induced by TCR/CD3-mediated activation. Cyclosporine 0-13 interleukin 2 receptor subunit alpha Homo sapiens 93-104 7929104-6 1994 Furthermore, cyclosporin A, which blocked TNF alpha production induced by PKC, strongly inhibited IL-2R alpha and NF.kappa B activation. Cyclosporine 13-26 interleukin 2 receptor subunit alpha Homo sapiens 98-109 7929104-7 1994 The addition of either TNF alpha or IL-2 partially recovered cyclosporin A-induced IL-2R alpha inhibition, but only TNF alpha completely recovered NF.kappa B activation. Cyclosporine 61-74 interleukin 2 receptor subunit alpha Homo sapiens 83-94 8278994-8 1993 Analysis of sections of recipients" spleens showed that spleen cell/CsA therapy led to significant reductions versus untreated controls, in expression of IL-2, IFN-gamma, and IL-2R. Cyclosporine 68-71 interleukin 2 receptor subunit alpha Homo sapiens 175-180 8137548-10 1994 Treatment with low-dose cyclosporin A (CsA) or FK506 in combination with BRC has proved more effective than either drug alone in suppression of T cell proliferation and CD25 antigen expression. Cyclosporine 24-37 interleukin 2 receptor subunit alpha Homo sapiens 169-173 8137548-10 1994 Treatment with low-dose cyclosporin A (CsA) or FK506 in combination with BRC has proved more effective than either drug alone in suppression of T cell proliferation and CD25 antigen expression. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 169-173 8500270-5 1993 T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. Cyclosporine 49-61 interleukin 2 receptor subunit alpha Homo sapiens 18-22 7678231-14 1993 As reported for IL-2R and IL-4R, our data also show that the expression of another T cell growth factor receptor is sensitive to the effects of cyclosporin A and FK506. Cyclosporine 144-157 interleukin 2 receptor subunit alpha Homo sapiens 16-21 7511004-11 1993 Flow cytometric analysis of peripheral blood cells prior to treatment with Cyclosporin-A showed systemic activation of lymphocytes, with high levels of HLA-DR and CD25 expression and a raised CD4/CD8 ratio. Cyclosporine 75-88 interleukin 2 receptor subunit alpha Homo sapiens 163-167 1289145-6 1992 A further 4 patients with retinal vasculitis who had been treated with cyclosporin A demonstrated a 32% reduction in IL2-R expression over a 3-month period. Cyclosporine 71-84 interleukin 2 receptor subunit alpha Homo sapiens 117-122 1325148-6 1992 We have performed a study in renal graft recipients in order to assess the usefulness of circulating S-IL-2R particularly to discriminate the origin of renal failure in cases of rejection or of cyclosporin-A (CsA)-induced nephrotoxicity. Cyclosporine 194-207 interleukin 2 receptor subunit alpha Homo sapiens 103-108 1325148-6 1992 We have performed a study in renal graft recipients in order to assess the usefulness of circulating S-IL-2R particularly to discriminate the origin of renal failure in cases of rejection or of cyclosporin-A (CsA)-induced nephrotoxicity. Cyclosporine 209-212 interleukin 2 receptor subunit alpha Homo sapiens 103-108 1346344-2 1992 In view of the importance of the IL-2 receptors in the expression of antiallograft immunity and the currently existing controversy regarding the effect of CsA on the induction of IL-2 receptors, we explored the effect of cyclosporine on the induction of interleukin-2 receptor alpha and beta in normal human T cells. Cyclosporine 221-233 interleukin 2 receptor subunit alpha Homo sapiens 254-282 1346344-5 1992 Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta. Cyclosporine 42-45 interleukin 2 receptor subunit alpha Homo sapiens 72-91 1346344-5 1992 Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta. Cyclosporine 42-45 interleukin 2 receptor subunit alpha Homo sapiens 331-350 2033128-4 1991 After 15 days of cyclosporine therapy, we observed a dramatic decrease in the total number of T cells and a corresponding decrease in interleukin 2 receptor-positive activated CD25+ cells and in antigen-presenting cells (CD1+ and CD14b+). Cyclosporine 17-29 interleukin 2 receptor subunit alpha Homo sapiens 176-180 2965735-7 1988 Cyclosporin A completely inhibited the PWM-induced development of CD25+ cells and related tissue damage. Cyclosporine 0-13 interleukin 2 receptor subunit alpha Homo sapiens 66-70 1700506-13 1990 Thus, in CsA sensitive individuals, one-tenth of the optimal CsA concentration together with CD25 antibody maintained maximum immunosuppression in vitro. Cyclosporine 9-12 interleukin 2 receptor subunit alpha Homo sapiens 93-97 2129797-1 1990 We have examined the effect and potential mechanism of Cyclosporin A (CsA) on the Interleukin-2-receptor alpha chain (IL-2R alpha) expression in human T-lymphocytes. Cyclosporine 70-73 interleukin 2 receptor subunit alpha Homo sapiens 118-129 2129797-2 1990 CsA pretreatment of PHA-activated T-cells led to 30-50% decrease in Tac antigen surface expression and a concomitant decrease in the steady state IL-2R alpha mRNA levels. Cyclosporine 0-3 interleukin 2 receptor subunit alpha Homo sapiens 68-79 2129797-2 1990 CsA pretreatment of PHA-activated T-cells led to 30-50% decrease in Tac antigen surface expression and a concomitant decrease in the steady state IL-2R alpha mRNA levels. Cyclosporine 0-3 interleukin 2 receptor subunit alpha Homo sapiens 146-157 2382107-5 1990 Sensitivity to CsA was expressed as the ability of the drug to suppress cell proliferation ([3H]thymidine incorporation) and high-affinity interleukin-2 receptor (IL-2R) expression. Cyclosporine 15-18 interleukin 2 receptor subunit alpha Homo sapiens 139-161 2382107-5 1990 Sensitivity to CsA was expressed as the ability of the drug to suppress cell proliferation ([3H]thymidine incorporation) and high-affinity interleukin-2 receptor (IL-2R) expression. Cyclosporine 15-18 interleukin 2 receptor subunit alpha Homo sapiens 163-168 2382107-10 1990 The CsA-induced suppression of high-affinity IL-2R expression varied between 57.1 and 98.9%, while suppression of [3H]thymidine incorporation varied between 81.0 and 97.4%. Cyclosporine 4-7 interleukin 2 receptor subunit alpha Homo sapiens 45-50 2312149-0 1990 Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Cyclosporine 147-160 interleukin 2 receptor subunit alpha Homo sapiens 45-48 2312149-4 1990 Thus, CsA affected IL-2R expression and/or function at higher concentrations (300 ng/ml). Cyclosporine 6-9 interleukin 2 receptor subunit alpha Homo sapiens 19-24 2312149-8 1990 However, addition of rIL-2 reversed CsA inhibition of IL-2R expression. Cyclosporine 36-39 interleukin 2 receptor subunit alpha Homo sapiens 54-59 2312149-9 1990 It is concluded that CsA, at least in anti-CD3-stimulated cells, inhibits IL-2R expression and cell proliferation with similar potency. Cyclosporine 21-24 interleukin 2 receptor subunit alpha Homo sapiens 74-79 2312149-10 1990 Exogenous rIL-2 reverses CsA inhibition of IL-2R expression. Cyclosporine 25-28 interleukin 2 receptor subunit alpha Homo sapiens 43-48 35043423-7 2022 Estimated baseline target antigen (CD25) level was lower is patients cotreated with cyclosporine (p=0.026). Cyclosporine 84-96 interleukin 2 receptor subunit alpha Homo sapiens 35-39 2789115-0 1989 In vitro and in vivo action of cyclosporin A on the induction of human interleukin-2 receptor alpha and beta chains. Cyclosporine 31-44 interleukin 2 receptor subunit alpha Homo sapiens 71-99 2539282-3 1989 In the present study using two-color analysis, we monitored the expression of interleukin-2 receptor (IL-2R) and HLA-DR antigen on the T-cells of a group of 51 renal cadaveric allograft recipients receiving cyclosporin, azathioprine, and prednisone for an average of 4 months after transplantation. Cyclosporine 207-218 interleukin 2 receptor subunit alpha Homo sapiens 78-100 2539282-3 1989 In the present study using two-color analysis, we monitored the expression of interleukin-2 receptor (IL-2R) and HLA-DR antigen on the T-cells of a group of 51 renal cadaveric allograft recipients receiving cyclosporin, azathioprine, and prednisone for an average of 4 months after transplantation. Cyclosporine 207-218 interleukin 2 receptor subunit alpha Homo sapiens 102-107 2903210-3 1988 IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3. Cyclosporine 58-71 interleukin 2 receptor subunit alpha Homo sapiens 39-45 2903210-3 1988 IL-2 transcripts peaked at 8-16 h, and IL-2-R at 24-40 h. Cyclosporin A (CSA) inhibited the synthesis of IL-2, but not IL-2-R mRNA, after stimulation by PHA or anti-CD3. Cyclosporine 73-76 interleukin 2 receptor subunit alpha Homo sapiens 39-45 2269327-4 1990 Here we show that as soon as 4 h after CsA addition, the transcription of the gene encoding the alpha chain (p55) of IL2R was inhibited. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 109-112 2269327-4 1990 Here we show that as soon as 4 h after CsA addition, the transcription of the gene encoding the alpha chain (p55) of IL2R was inhibited. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 117-121 2269327-10 1990 This discrepancy between the effect of CsA on IL2R alpha expression as probed at the mRNA or the protein level can be accounted for by the stability of the IL2R alpha protein after synthesis. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 46-56 2269327-10 1990 This discrepancy between the effect of CsA on IL2R alpha expression as probed at the mRNA or the protein level can be accounted for by the stability of the IL2R alpha protein after synthesis. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 156-166 1967265-8 1990 Transcripts of the gene for the IL-2R p55 chain are also normally elevated during infection, and CsA treatment resulted in an 80% reduction in the percentage of cells transcribing this gene. Cyclosporine 97-100 interleukin 2 receptor subunit alpha Homo sapiens 32-37 1967265-8 1990 Transcripts of the gene for the IL-2R p55 chain are also normally elevated during infection, and CsA treatment resulted in an 80% reduction in the percentage of cells transcribing this gene. Cyclosporine 97-100 interleukin 2 receptor subunit alpha Homo sapiens 38-41 2544432-14 1989 CsA blocks the T3-II-induced potentiation of PMA-induced IL2R expression but not the mAb 9.3-induced potentiation. Cyclosporine 0-3 interleukin 2 receptor subunit alpha Homo sapiens 57-61 2544432-15 1989 This differential inhibitory effect of CsA on IL2R expression is also seen with db-cAMP and CT. We examined the effects of these two pathways on the expression of the early activation antigen EA 1 and cytoplasmic free calcium. Cyclosporine 39-42 interleukin 2 receptor subunit alpha Homo sapiens 46-50 2783946-11 1989 Furthermore, IL-4 could augment proliferation and IL-2R expression of T cells stimulated with PHA in the presence of cyclosporin A, which blocks endogenous cytokine production or anti-Tac. Cyclosporine 117-130 interleukin 2 receptor subunit alpha Homo sapiens 50-55 3263432-7 1988 Treatment with CsA during induction of competence prevented the expression of the 55-kDa IL-2R gene during competence induction and inhibited IL-2 gene expression and IL-2 production in response to PDB in the second phase. Cyclosporine 15-18 interleukin 2 receptor subunit alpha Homo sapiens 89-94 3136569-4 1988 Using 125I-labeled human recombinant IL-2 and 125I-labeled 33B3.1 (a MoAb directed against TAC antigen), we found that expression of both high and low affinity sites was decreased when clone cells were stimulated with D.BLCL in the presence of CsA and exogenous IL-2 (about 50% inhibition in the presence of 500 ng/ml of CsA). Cyclosporine 244-247 interleukin 2 receptor subunit alpha Homo sapiens 91-102 3136569-4 1988 Using 125I-labeled human recombinant IL-2 and 125I-labeled 33B3.1 (a MoAb directed against TAC antigen), we found that expression of both high and low affinity sites was decreased when clone cells were stimulated with D.BLCL in the presence of CsA and exogenous IL-2 (about 50% inhibition in the presence of 500 ng/ml of CsA). Cyclosporine 321-324 interleukin 2 receptor subunit alpha Homo sapiens 91-102 3096881-1 1986 The effect of cyclosporine A (CsA) on the mitogen-induced expression of Interleukin 2 receptor (IL2R) and transferrin receptor (TR) was monitored using receptor-specific monoclonal antibodies and flow cytometry. Cyclosporine 30-33 interleukin 2 receptor subunit alpha Homo sapiens 72-94 2896111-0 1988 Cyclosporin A does not inhibit the PHA-stimulated increase in intracellular Ca2+ concentration but inhibits the increase in E-rosette receptor (CD2) expression and appearance of interleukin-2 receptors (CD25). Cyclosporine 0-13 interleukin 2 receptor subunit alpha Homo sapiens 203-207 3096881-1 1986 The effect of cyclosporine A (CsA) on the mitogen-induced expression of Interleukin 2 receptor (IL2R) and transferrin receptor (TR) was monitored using receptor-specific monoclonal antibodies and flow cytometry. Cyclosporine 30-33 interleukin 2 receptor subunit alpha Homo sapiens 96-100 3096881-2 1986 For all mitogens tested (PHA, Con A, OKT3, and Leu 4), expression of IL2R and TR, as well as DNA synthesis (3H-thymidine incorporation), were significantly reduced in the presence of CsA (0.5 microgram/ml). Cyclosporine 183-186 interleukin 2 receptor subunit alpha Homo sapiens 69-73 3096881-3 1986 Titration experiments in the OKT3 system, the mitogen system most profoundly affected by CsA, revealed that CsA concentrations as low as 0.05 microgram/ml inhibited IL2R and TR expression and DNA synthesis, and that changes in DNA synthesis reflected changes in IL2R and TR expression. Cyclosporine 108-111 interleukin 2 receptor subunit alpha Homo sapiens 165-169 3096881-3 1986 Titration experiments in the OKT3 system, the mitogen system most profoundly affected by CsA, revealed that CsA concentrations as low as 0.05 microgram/ml inhibited IL2R and TR expression and DNA synthesis, and that changes in DNA synthesis reflected changes in IL2R and TR expression. Cyclosporine 108-111 interleukin 2 receptor subunit alpha Homo sapiens 262-266 3096881-4 1986 The addition of exogenous IL2 partially abrogated the CsA-mediated inhibition of all three activation parameters (IL2R, TR, DNA synthesis) in response to PHA, OKT3, and Leu 4. Cyclosporine 54-57 interleukin 2 receptor subunit alpha Homo sapiens 114-118 3096881-6 1986 These findings indicate that CsA inhibits mitogen-induced expression of IL2R and TR, and for some mitogen systems, this inhibition appears, at least in part, to be secondary to decreased IL2 production. Cyclosporine 29-32 interleukin 2 receptor subunit alpha Homo sapiens 72-76 6406595-2 1983 In the present study, we examined the effect of cyclosporin A (CsA) on the expression of Tac antigen by mitogen-stimulated T cells. Cyclosporine 63-66 interleukin 2 receptor subunit alpha Homo sapiens 89-100 3926357-1 1985 The effect of cyclosporine A (CyA) on the expression of the Tac-antigen (IL-2 receptor) on PHA-activated PBMNC was analysed by immunofluorescence. Cyclosporine 14-28 interleukin 2 receptor subunit alpha Homo sapiens 60-71 28257599-7 2017 Treatment with tacrolimus and cyclosporin render CD4+ CD25- cells more susceptible to Treg control. Cyclosporine 30-41 interleukin 2 receptor subunit alpha Homo sapiens 54-58 27367933-1 2016 The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax , a distinct form of daclizumab, which was approved for the prevention of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. Cyclosporine 387-399 interleukin 2 receptor subunit alpha Homo sapiens 4-8